critical importance of understanding g6pd
TRANSCRIPT
Critical Importance of Understanding G6PD in Drug Therapy OptionsProduct Analyzer Description
Reagent
G7583-180 Open Channel R1: 10 x 6 mL, R2 1 x 120 mL
Lyse
Control
G7583-LYS 1 x 100 mL
G7583-CTL Lyophilized 2 x 0.5 mL Deficient Ctl2 x 0.5 mL Intermediate Ctl2 x 0.5 mL Normal Ctl
ORDERING INFORMATION: G6PD
Reagent
H7504-120 Open Channel 1 x 120 mL
ORDERING INFORMATION: HEMOGLOBINProduct Analyzer Description
Control
Standard
H7506-6 3 x 2 mL
H7506-STD 1 x 2 mL
REFERENCES1. Beutler, Ernest. “G6PD Deficiency.” The American Society of Hematology, vol. 84, no. 11, 25 Aug. 1994, pp. 3613–3636.
2. Bubp, Jeff. “Caring for Glucose-6-Phosphate Dehydrogenase (G6PD)–Deficient Patients: Implications for Pharmacy.” P&T, vol. 40, no. 9, Sept. 2015, pp. 572–574.
3. Frank, Jennifer. “Diagnosis and Management of G6PD Deficiency.” American Family Physician, vol. 72, no. 7, 1 Oct. 2005, pp. 1277–1282.
4. Murray, Clinton. “Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in U.S. Army Personnel.” Military Medicine, vol. 171, Sept. 2006, pp. 905–907.
5. “A Genetic Deficiency That Can Lead to Anemia.” G6PD, Indiana Hemophilia & Thrombosis Center, INC., www.ihtc.org/G6PD/.
6. Pal, Sampa, et al. “Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient.” US National Library of Medicine National Institues of Health, The American Society of Tropical Medicine and Hygiene, 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC6335905/pdf/tpmd180612.pdf.
800.445.9853www.medtestdx.com
BR-G7583-01
Applications available for wide range of analyzers
Exploration of G6PD Deficiency
400 MillionPeopleWorldwidelive withG6PDDeficiency1,2
Class Level of Severity G6PD Activity(% of Normal)
Units per Gram ofHemoglobin (U/g Hb)
I
III
II
V
High
Mild to Moderate
High
None
Severe enzyme deficiency
10% - 60%
<10%
>150%
0.12
1.3 - 7.1
0.13 - 0.12
>17.7
Most common enzymatic blooddisorder
Requires a medical diagnosis; labscreening always required
Exposure to specific triggers may result inhemolytic crisis*
Treatment can help, but this condition cannot be cured
IV Mild to None 60% - 150% 7.2 - 17.7
Why Testing Matters
It is critical to understand the patient’s exact level of severity prior to and during medical therapies, such as chemotherapy, to eliminate the risk of severe adverse reactions
An individual’s G6PD enzyme activity may shift throughout their life making it important to know their current level of severity in order to maintain a healthy lifestyle 2
Key Facts:
Early diagnosis of G6PD deficiency in newborns enables health care professionals to educate parents on which triggers to avoid that may cause a hemolytic crisis 3
Performing G6PD screenings on militarypersonnel eliminates the risk of adverse reactionsfrom common anti-malaria drugs such as Primaquine, Chloroquine and its derivatives 4
ImprovedPatient
Outcomes
UnparalledAccuracy
StreamlinedSolution
“ Pointe brandGlucose-6-Phosphate
Dehydrogenase (G6PD) is the only 510(k) cleared, CE marked quantitative reagent manufactured
in the USA.
“Quantitative test results provides a specific level of severity (see table 1, column 2)
Elimination of a qualitative screen by starting with quantitative screen
Run our hemoglobin assay concurrently on the same analyzer as the G6PD assay
Correlation Coefficient of 0.994
Manufactured under ISO 13485standards
Enzymatic method assay requires nocalibrator
Time savings with 5-minute lysing step
One source supplier of reagent, lyse, control and hemoglobin assay
A Few of the MANY Triggers Include: Rasburicase, Vitamin K, Sulfa Drugs, Quinolone Antibiotics, Nitrofurantoin, Aspirin, Primaquine, Penicillamine, Fava Beans 5
The Pointe Brand G6PD is the Superior Choice
*Hemolytic crisis can result in death
1,2
Table 1: The levels of G6PD deficiency as defined by the World Health Organization (WHO)
SuperiorOperations
Eliminate subjective test results from visual observation of color change
Reduction in scrap-rate due to 24 month shelf-life
Onboard lyse capabilities
Pointe brand reagents for G6PD spectrophotometry testing isconsidered the gold standard for the sensitive and accuratequantitative determination of G6PD in blood.6 Unlike other G6PDassays, which require a total of 30 minutes of sample preparationsteps, the Pointe brand G6PD assay requires only a single 5-minute lysing step and can be on-board lysed, reducing the time to resultsof the determination of G6PD activity levels in whole blood.
Exploration of G6PD Deficiency
400 MillionPeopleWorldwidelive withG6PDDeficiency1,2
Class Level of Severity G6PD Activity(% of Normal)
Units per Gram ofHemoglobin (U/g Hb)
I
III
II
V
High
Mild to Moderate
High
None
Severe enzyme deficiency
10% - 60%
<10%
>150%
0.12
1.3 - 7.1
0.13 - 0.12
>17.7
Most common enzymatic blooddisorder
Requires a medical diagnosis; labscreening always required
Exposure to specific triggers may result inhemolytic crisis*
Treatment can help, but this condition cannot be cured
IV Mild to None 60% - 150% 7.2 - 17.7
Why Testing Matters
It is critical to understand the patient’s exact level of severity prior to and during medical therapies, such as chemotherapy, to eliminate the risk of severe adverse reactions
An individual’s G6PD enzyme activity may shift throughout their life making it important to know their current level of severity in order to maintain a healthy lifestyle 2
Key Facts:
Early diagnosis of G6PD deficiency in newborns enables health care professionals to educate parents on which triggers to avoid that may cause a hemolytic crisis 3
Performing G6PD screenings on militarypersonnel eliminates the risk of adverse reactionsfrom common anti-malaria drugs such as Primaquine, Chloroquine and its derivatives 4
ImprovedPatient
Outcomes
UnparalledAccuracy
StreamlinedSolution
“ Pointe brandGlucose-6-Phosphate
Dehydrogenase (G6PD) is the only 510(k) cleared, CE marked quantitative reagent manufactured
in the USA.
“Quantitative test results provides a specific level of severity (see table 1, column 2)
Elimination of a qualitative screen by starting with quantitative screen
Run our hemoglobin assay concurrently on the same analyzer as the G6PD assay
Correlation Coefficient of 0.994
Manufactured under ISO 13485standards
Enzymatic method assay requires nocalibrator
Time savings with 5-minute lysing step
One source supplier of reagent, lyse, control and hemoglobin assay
A Few of the MANY Triggers Include: Rasburicase, Vitamin K, Sulfa Drugs, Quinolone Antibiotics, Nitrofurantoin, Aspirin, Primaquine, Penicillamine, Fava Beans 5
The Pointe Brand G6PD is the Superior Choice
*Hemolytic crisis can result in death
1,2
Table 1: The levels of G6PD deficiency as defined by the World Health Organization (WHO)
SuperiorOperations
Eliminate subjective test results from visual observation of color change
Reduction in scrap-rate due to 24 month shelf-life
Onboard lyse capabilities
Pointe brand reagents for G6PD spectrophotometry testing isconsidered the gold standard for the sensitive and accuratequantitative determination of G6PD in blood.6 Unlike other G6PDassays, which require a total of 30 minutes of sample preparationsteps, the Pointe brand G6PD assay requires only a single 5-minute lysing step and can be on-board lysed, reducing the time to resultsof the determination of G6PD activity levels in whole blood.
Critical Importance of Understanding G6PD in Drug Therapy OptionsProduct Analyzer Description
Reagent
G7583-180 Open Channel R1: 10 x 6 mL, R2 1 x 120 mL
Lyse
Control
G7583-LYS 1 x 100 mL
G7583-CTL Lyophilized 2 x 0.5 mL Deficient Ctl2 x 0.5 mL Intermediate Ctl2 x 0.5 mL Normal Ctl
ORDERING INFORMATION: G6PD
Reagent
H7504-120 Open Channel 1 x 120 mL
ORDERING INFORMATION: HEMOGLOBINProduct Analyzer Description
Control
Standard
H7506-6 3 x 2 mL
H7506-STD 1 x 2 mL
REFERENCES1. Beutler, Ernest. “G6PD Deficiency.” The American Society of Hematology, vol. 84, no. 11, 25 Aug. 1994, pp. 3613–3636.
2. Bubp, Jeff. “Caring for Glucose-6-Phosphate Dehydrogenase (G6PD)–Deficient Patients: Implications for Pharmacy.” P&T, vol. 40, no. 9, Sept. 2015, pp. 572–574.
3. Frank, Jennifer. “Diagnosis and Management of G6PD Deficiency.” American Family Physician, vol. 72, no. 7, 1 Oct. 2005, pp. 1277–1282.
4. Murray, Clinton. “Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in U.S. Army Personnel.” Military Medicine, vol. 171, Sept. 2006, pp. 905–907.
5. “A Genetic Deficiency That Can Lead to Anemia.” G6PD, Indiana Hemophilia & Thrombosis Center, INC., www.ihtc.org/G6PD/.
6. Pal, Sampa, et al. “Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient.” US National Library of Medicine National Institues of Health, The American Society of Tropical Medicine and Hygiene, 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC6335905/pdf/tpmd180612.pdf.
800.445.9853www.medtestdx.com
BR-G7583-01
Applications available for wide range of analyzers